Home › Metastatic Cancer › Texas › Irving
Metastatic Cancer clinical trials in Irving, TX
10 studies for Metastatic Cancer are looking for participants at sites in and around Irving (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors
RecruitingPhase 1
- NEXT Oncology Dallas, Irving
AMG 436 as Monotherapy and Combination Therapy in Participants With MSI-H/dMMR Solid Tumors
RecruitingPhase 1
- Next Oncology - Dallas, Irving
Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingPhase 1/2
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center, Irving
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingPhase 3
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center, Irving
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingPhase 3
- US Oncology Investigational Products Center (IPC), Irving
- US Oncology Investigational Products Center, Irving
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
RecruitingPhase 1/2
- Avenzo Therapeutics Recruiting Site, Irving
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
RecruitingPhase 1
- NEXT Oncology Dallas, Irving
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
RecruitingPhase 1/2
- NEXT Dallas, Irving
A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.
RecruitingPhase 1
- NEXT Oncology, Irving
A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
RecruitingPhase 1/2
- NEXT Dallas, Irving
Metastatic Cancer trials in other cities
- Houston, TX100 studies
- New York City, NY93 studies
- Nashville, TN69 studies
- Boston, MA61 studies
- Los Angeles, CA57 studies
- Arlington, VA52 studies
- St. Louis, MO52 studies
- San Antonio, TX44 studies
- Washington, DC44 studies
- Dallas, TX44 studies
- Philadelphia, PA42 studies
- Chicago, IL42 studies
Other studies in Irving
- Non-Small Cell Lung Cancer23 studies
- Colorectal Cancer15 studies
- Cancer (all types)14 studies
- Stomach Cancer9 studies
- Head and Neck Squamous Cell Carcinoma8 studies
- Breast Cancer8 studies
- Pancreatic Cancer7 studies
- Ovarian Cancer7 studies
- Small Cell Lung Cancer6 studies
- Endometrial Cancer6 studies
- Esophageal Cancer5 studies
- Lung Cancer5 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.